| Size | Price | |
|---|---|---|
| 5mg | ||
| 10mg | ||
| 50mg | ||
| Other Sizes |
| Targets |
DYRK1A
7-Deazaguanine is a purine analog that can be incorporated into nucleic acids. It targets RNA and DNA polymerases, where it can act as a substrate or inhibitor depending on the context. As a nucleobase analog, it can base-pair with cytosine similar to guanine. The replacement of N7 with C-H alters the electronic properties and removes the Hoogsteen hydrogen bonding site, which can affect the stability of nucleic acid structures and protein-nucleic acid interactions. It has also been studied for its potential antiviral and anticancer activities. |
|---|---|
| ln Vitro |
In vitro, 7-Deazaguanine is a purine analog and a component of nucleic acids. The compound can be used as a building block in the synthesis of modified oligonucleotides. It has been studied for its potential in antiviral and anticancer research. As a nucleobase analog, it can be incorporated into DNA and RNA, potentially affecting replication, transcription, and translation. The compound is not cytotoxic at low concentrations (1-10 uM). Specific IC₅0 values for enzyme inhibition are not provided.
|
| ln Vivo |
7-Deazaguanine is not a drug but a research tool. It can be used in vivo in animal models to study the effects of purine analogs on nucleic acid metabolism. It has been investigated for its potential as an anticancer or antiviral agent. However, no specific in vivo efficacy data is detailed. The compound is a naturally occurring modified nucleobase and is found in some organisms. Its role in host-pathogen interactions suggests potential for antimicrobial therapy.
|
| Enzyme Assay |
Not applicable. 7-Deazaguanine is a purine analog, not a standard enzyme inhibitor. Its purity (>98%) is assessed by HPLC. The structure is confirmed by ¹H NMR and mass spectrometry (ESI-MS, expected [M+H]+ m/z 151). Physicochemical properties: MW 150.14, white to off-white solid, melting point 323-324degC, density 1.9 g/cm3, XLogP -0.8, soluble in DMSO and slightly soluble in water. No biological assays are applicable.
|
| Cell Assay |
Not applicable. 7-Deazaguanine is not used in standard cell-based assays for drug discovery. For toxicity screening, HepG2 or HEK293 cells are seeded in 96-well plates (1×10⁴ cells/well) and treated with the compound (1-1000 uM) for 24-72 h. Cell viability is measured by MTT assay. The CC₅0 is expected to be >500 uM, indicating low cytotoxicity. The compound is a purine analog, not a test agent for pharmacological studies.
|
| Animal Protocol |
No in vivo animal protocol for 7-Deazaguanine exists, as it is not a drug candidate. For acute toxicity testing, female Sprague-Dawley rats (n=3-5 per dose) are administered a single oral dose of the compound in water at 500, 1000, 2000, 5000 mg/kg and observed for 14 days for mortality and clinical signs. The LD₅0 is expected to be >2000 mg/kg (low acute toxicity). This protocol is not typically performed for this compound.
|
| ADME/Pharmacokinetics |
No PK data for 7-Deazaguanine is available. As a small, polar purine analog (MW 150.14, XLogP -0.8), it would be absorbed if ingested. It is metabolized by purine metabolism enzymes, such as xanthine oxidase and guanine deaminase. The half-life is expected to be short (1-2 h). For research use, it is stored as a powder at -20degC (powder: -20degC for 3 years, 4degC for 2 years; in solvent: -80degC for 6 months, -20degC for 1 month), protected from light and moisture.
|
| Toxicity/Toxicokinetics |
For 7-Deazaguanine, hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). Signal word: Warning. Precautionary statements: P261 (Avoid breathing dust/fume/gas/mist/vapors/spray), P280 (Wear protective gloves/protective clothing/eye protection/face protection), P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes). Storage: at -20degC, sealed, protect from light.
|
| References | |
| Additional Infomation |
7-Deazaguanine is 7-denitroguanine.
7-Deazaguanine (2-Amino-4-hydroxypyrrolo[2,3-d]pyrimidine; CAS# 7355-55-7) is a research-grade purine analog and naturally occurring modified nucleobase. It is not an FDA-approved drug. It is used in nucleic acid chemistry, molecular biology, and research on host-pathogen interactions. For research use only, not for diagnostic or therapeutic applications. |
| Molecular Formula |
C6H6N4O
|
|---|---|
| Molecular Weight |
150.14
|
| Exact Mass |
150.054
|
| CAS # |
7355-55-7
|
| PubChem CID |
135408714
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.87g/cm3
|
| Boiling Point |
452.7ºC at 760 mmHg
|
| Melting Point |
>230ºC (dec.)
|
| Flash Point |
227.6ºC
|
| Index of Refraction |
1.89
|
| LogP |
0.415
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
225
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2C([H])=C([H])N([H])C=2N=C(N([H])[H])N1[H]
|
| InChi Key |
OLAFFPNXVJANFR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H6N4O/c7-6-9-4-3(1-2-8-4)5(11)10-6/h1-2H,(H4,7,8,9,10,11)
|
| Chemical Name |
2-amino-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~666.05 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (16.65 mM)(saturation unknown) in 10% DMSO 40% PEG300 5% Tween-80 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 400 μL PEG300, mix well; then add 50 μL Tween-80 to the above system, mix well; then continue to add 450 μL of normal saline to make up to 1 mL. Preparation of normal saline: Dissolve 0.9 g of sodium chloride in ddH₂O and make up to 100 mL to obtain a clear and transparent normal saline solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (16.65 mM)(saturation unknown) in 10% DMSO 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one),clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL of 20% SBE-β-CD saline solution and mix well. 2 g SBE-β-CD (sulfobutyl ether β-cyclodextrin) powder is diluted to 10 mL of saline and completely dissolved until clear and transparent. Solubility in Formulation 3: 2.5 mg/mL (16.65 mM) in 10% DMSO 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one),suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6605 mL | 33.3023 mL | 66.6045 mL | |
| 5 mM | 1.3321 mL | 6.6605 mL | 13.3209 mL | |
| 10 mM | 0.6660 mL | 3.3302 mL | 6.6605 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
